Quantitative promoter methylation differentiates carcinoma ex pleomorphic adenoma from pleomorphic salivary adenoma

British Journal of Cancer

Volumn 103, Issue 12, 2010, Pages 1846-1851

  Schache, A G ^a,b   Hall, G ^c   Woolgar, J A ^a   Nikolaidis, G ^a   Triantafyllou, A ^a   Lowe, D ^d   Risk, J M ^a   Shaw, R J ^a,b   Liloglou, T ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d EDGE HILL UNIVERSITY   (United Kingdom)

Author keywords

carcinoma ex pleomorphic adenoma; methylation; salivary gland tumour

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; CONTROLLED STUDY; CYGP GENE; HUMAN; MALIGNANT TRANSFORMATION; METHYLATION; PRIORITY JOURNAL; PROMOTER METHYLATION; PROMOTER REGION; RAR BETA GENE; REAL TIME POLYMERASE CHAIN REACTION; SALIVARY GLAND ADENOMA; SALIVARY GLAND CARCINOMA; SALIVARY GLAND CARCINOMA EX PLEOMORPHIC ADENOMA; SALIVARY GLAND TUMOR; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

ADENOMA, PLEOMORPHIC; DNA METHYLATION; GENES, TUMOR SUPPRESSOR; HUMANS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; SALIVARY GLAND NEOPLASMS; TELOMERASE; WT1 PROTEINS;

EID: 78650006960     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605953     Document Type: Article

References (36)

1. Augello C, Gregorio V, Bazan V, Cammareri P, Agnese V, Cascio S, Corsale S, Calo V, Gullo A, Passantino R, Gargano G, Bruno L, Rinaldi G, Morello V, Gerbino A, Tomasino RM, Macaluso M, Surmacz E, Russo A (2006) TP53 and p16INK4A, but not H-KI-Ras, are involved in tumorigenesis and progression of pleomorphic adenomas. J Cell Physiol 207: 654-659
2. Banerjee SK, Makdisi WF, Weston AP, Mitchell SM, Campbell DR (1995) Microwave-based DNA extraction from paraffin-embedded tissue for PCR amplification. Biotechniques 18: 768-770, 772-773
3. Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, Basu S, Fidler M, Walters K, Bonomi P, Coon J (2010) PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer 126: 1630-1639
4. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M, Minna JD (2001) Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93: 691-699
5. Chatagnon A, Bougel S, Perriaud L, Lachuer J, Benhattar J, Dante R (2009) Specific association between the methyl-CpG-binding domain protein 2 and the hypermethylated region of the human telomerase reverse transcriptase promoter in cancer cells. Carcinogenesis 30: 28-34
6. Donninger H, Vos MD, Clark GJ (2007) The RASSF1A tumor suppressor. J Cell Sci 120: 3163-3172
7. Ellis GL, Auclair PL (1996) Malignant epithelial tumours. In Atlas of Tumour Pathology, Ellis GL, Auclair PL (eds) pp 155-373. Armed Forces Institute of Pathology: Washington, DC
8. Eneroth CM, Zetterberg A (1974) Malignancy in pleomorphic adenoma. A clinical and microspectrophotometric study. Acta Otolaryngol 77: 426-432
9. Ghosh S, Ghosh A, Maiti GP, Alam N, Roy A, Roy B, Roychoudhury S, Panda CK (2008) Alterations of 3p21.31 tumor suppressor genes in head and neck squamous cell carcinoma: Correlation with progression and prognosis. Int J Cancer 123: 2594-2604
10. Gnepp W (1991) Malignant mixed tumours. In Surgical Pathology of the Salivary Glands, Ellis GL, Auclair PL, Gnepp DR (eds) pp 350-368. Saunders: Philadelphia
11. Hall GL, Shaw RJ, Field EA, Rogers SN, Sutton DN, Woolgar JA, Lowe D, Liloglou T, Field JK, Risk JM (2008) p16 Promoter methylation is a potential predictor of malignant transformation in oral epithelial dysplasia. Cancer Epidemiol Biomarkers Prev 17: 2174-2179
12. Huang KH, Huang SF, Chen IH, Liao CT, Wang HM, Hsieh LL (2009) Methylation of RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma. Clin Cancer Res 15: 4174-4180
13. Iliopoulos D, Oikonomou P, Messinis I, Tsezou A (2009) Correlation of promoter hypermethylation in hTERT, DAPK and MGMT genes with cervical oncogenesis progression. Oncol Rep 22: 199-204
14. Jeronimo C, Usadel H, Henrique R, Oliveira J, Lopes C, Nelson WG, Sidransky D (2001) Quantitation of GSTP1 methylation in nonneoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 93: 1747-1752
15. Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Yamada H, Yamamoto R, Sakuragi N, Enokida H, Verma M, Dahiya R (2005) WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer 104: 1924-1930
16. Katori H, Nozawa A, Tsukuda M (2007) Expression of epidermal growth factor receptor, transforming growth factor-alpha and Ki-67 in relationship to malignant transformation of pleomorphic adenoma. Acta Otolaryngol 127: 1207-1213
17. Klijanienko J, El-Naggar AK, Vielh P (1999) Fine-needle sampling findings in 26 carcinoma ex pleomorphic adenomas: Diagnostic pitfalls and clinical considerations. Diagn Cytopathol 21: 163-166
18. Kumari A, Srinivasan R, Vasishta RK, Wig JD (2009) Positive regulation of human telomerase reverse transcriptase gene expression and telomerase activity by DNA methylation in pancreatic cancer. Ann Surg Oncol 16: 1051-1059
19. Lai HC, Lin YW, Huang TH, Yan P, Huang RL, Wang HC, Liu J, Chan MW, Chu TY, Sun CA, Chang CC, Yu MH (2008) Identification of novel DNA methylation markers in cervical cancer. Int J Cancer 123: 161-167
20. Lee ES, Issa JP, Roberts DB, Williams MD, Weber RS, Kies MS, El-Naggar AK (2008) Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: Comparison with methylation-specific PCR technique and clinical significance. Clin Cancer Res 14: 2664-2672
21. Lewis JE, Olsen KD, Sebo TJ (2001) Carcinoma ex pleomorphic adenoma: Pathologic analysis of 73 cases. Hum Pathol 32: 596-604
22. Maruya S, Kim HW, Weber RS, Lee JJ, Kies M, Luna MA, Batsakis JG, El-Naggar AK (2004) Gene expression screening of salivary gland neoplasms: Molecular markers of potential histogenetic and clinical significance. J Mol Diagn 6: 180-190
23. Maruya S, Kurotaki H, Shimoyama N, Kaimori M, Shinkawa H, Yagihashi S (2003) Expression of p16 protein and hypermethylation status of its promoter gene in adenoid cystic carcinoma of the head and neck. ORL J Otorhinolaryngol Relat Spec 65: 26-32
24. Nagel H, Laskawi R, Eiffert H, Schlott T (2003) Analysis of the tumour suppressor genes, FHIT and WT-1, and the tumour rejection genes, BAGE, GAGE-1/2, HAGE, MAGE-1, and MAGE-3, in benign and malignant neoplasms of the salivary glands. Mol Pathol 56: 226-231
25. Oji Y, Inohara H, Nakazawa M, Nakano Y, Akahani S, Nakatsuka S, Koga S, Ikeba A, Abeno S, Honjo Y, Yamamoto Y, Iwai S, Yoshida K, Oka Y, Ogawa H, Yoshida J, Aozasa K, Kubo T, Sugiyama H (2003) Overexpression of the Wilms' tumor gene WT1 in head and neck squamous cell carcinoma. Cancer Sci 94: 523-529
26. Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, Soma T, Tatekawa T, Kawakami M, Asada M, Kishimoto T, Sugiyama H (1999) Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 90: 194-204
27. Olsen KD, Lewis JE (2001) Carcinoma ex pleomorphic adenoma: A clinicopathologic review. Head Neck 23: 705-712
28. Pannone G, De Maria S, Zamparese R, Metafora S, Serpico R, Morelli F, Rubini C, Farina E, Carteni M, Staibano S, De Rosa G, Lo Muzio L, Bufo P (2007) Prognostic value of human telomerase reverse transcriptase gene expression in oral carcinogenesis. Int J Oncol 30: 1349-1357
29. Patel RS, Rose B, Bawdon H, Hong A, Lee CS, Fredericks S, Gao K, O'Brien CJ (2007) Cyclin D1 and p16 expression in pleomorphic adenoma and carcinoma ex pleomorphic adenoma of the parotid gland. Histopathology 51: 691-696 (Pubitemid 47572878)
30. Shaw RJ, Hall GL, Lowe D, Bowers NL, Liloglou T, Field JK, Woolgar JA, Risk JM (2007) CpG island methylation phenotype (CIMP) in oral cancer: Associated with a marked inflammatory response and less aggressive tumour biology. Oral Oncol 43: 878-886
31. Shaw RJ, Liloglou T, Rogers SN, Brown JS, Vaughan ED, Lowe D, Field JK, Risk JM (2006) Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br J Cancer 94: 561-568
32. Shivakumar L, Minna J, Sakamaki T, Pestell R, White MA (2002) The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol 22: 4309-4318
33. Takakura M, Kyo S, Kanaya T, Hirano H, Takeda J, Yutsudo M, Inoue M (1999) Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 59: 551-557
34. Vargas PA, Cheng Y, Barrett AW, Craig GT, Speight PM (2008) Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumours. J Oral Pathol Med 37: 309-318
35. Widschwendter A, Muller HM, Hubalek MM, Wiedemair A, Fiegl H, Goebel G, Mueller-Holzner E, Marth C, Widschwendter M (2004) Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol Oncol 93: 407-416
36. Williams MD, Chakravarti N, Kies MS, Maruya S, Myers JN, Haviland JC, Weber RS, Lotan R, El-Naggar AK (2006) Implications of methylation patterns of cancer genes in salivary gland tumors. Clin Cancer Res 12: 7353-7358